{"title":"干细胞移植后艾滋病毒-1缓解，但无CCR5Δ32突变","authors":"","doi":"10.1038/s41591-024-03365-0","DOIUrl":null,"url":null,"abstract":"We report the first case of a person achieving sustained HIV-1 remission after transplantation with allogeneic hematopoietic stem cells that express wild-type CCR5 and thus are permissive to HIV-1 infection. The 53-year-old man received the transplant in 2018 to treat a rare myeloid sarcoma and has not experienced viral rebound since discontinuing antiretroviral therapy in November 2021.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"16 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIV-1 remission following stem cell transplant without CCR5Δ32 mutation\",\"authors\":\"\",\"doi\":\"10.1038/s41591-024-03365-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We report the first case of a person achieving sustained HIV-1 remission after transplantation with allogeneic hematopoietic stem cells that express wild-type CCR5 and thus are permissive to HIV-1 infection. The 53-year-old man received the transplant in 2018 to treat a rare myeloid sarcoma and has not experienced viral rebound since discontinuing antiretroviral therapy in November 2021.\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":58.7000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41591-024-03365-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-024-03365-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
HIV-1 remission following stem cell transplant without CCR5Δ32 mutation
We report the first case of a person achieving sustained HIV-1 remission after transplantation with allogeneic hematopoietic stem cells that express wild-type CCR5 and thus are permissive to HIV-1 infection. The 53-year-old man received the transplant in 2018 to treat a rare myeloid sarcoma and has not experienced viral rebound since discontinuing antiretroviral therapy in November 2021.
期刊介绍：
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
